Table 3.
Medical therapya for inflammatory bowel disease within the first year of diagnosis
| Therapy |
Crohn's disease N = 27 |
Ulcerative colitis N = 27 |
|---|---|---|
| Oral corticosteroids | ||
| Yes | 24 (89%) | 15 (56%) |
| No | 1 (4%) | 8 (30%) |
| Missing data | 2 (7%) | 4 (15%) |
| Oral 5-ASA | ||
| Yes | 18 (67%) | 17 (63%) |
| No | 7 (26%) | 6 (22%) |
| Missing data | 2 (7%) | 4 (15%) |
| Azathioprine | ||
| Yes | 21 (78%) | 9 (33%) |
| No | 4 (15%) | 14 (52%) |
| Missing data | 2 (7%) | 4 (15%) |
| Biologics | ||
| Yes | 9 (33%) | 1 (4%) |
| No | 16 (59%) | 22 (81%) |
| Missing data | 2 (7%) | 4 (15%) |
aData restricted to systemic medical therapy of 57 patients who had a validated (true) inflammatory bowel disease diagnosis on medical record review. Three patients with undefined inflammatory bowel disease (IBD) were not specifically reported in the table: three had oral corticosteroids, two with undefined IBD had 5-aminosalicylic acid (5-ASA), one had azathioprine and none of those three with undefined IBD had biologics